HaemaLogiX: • Proprietary, differentiated B cell targets engaged via antibody and CAR-T programs.
• KappaMab & LambdaMab only target malignant B cells, do not bind to normal immune cells.
o KappaMab plus RevDex Ph 2b in MM, data 2H20.
o Kappa CAR-T specific for target cells, no off tumour lysis. Capacity for dual-targeting with CD-19, BCMA, etc.
o LambdaMab in preclinical for amyloidosis.
• Raised $AUD8M since 2015; funded by current directors (56%) & 25 other primarily Australian investors.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Australia
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Hematology, Immuno-Oncology, Immunotherapy
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Private
Therapeutic Modalities
Antibodies
Website:
Address:
HaemaLogiX Pty. Ltd
Suite 204, Cicada Innovations, 4 Cornwallis St.
Eveleigh, NSW 2015
Australia

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.